| pubmed-article:17671689 | rdf:type | pubmed:Citation | lld:pubmed |
| pubmed-article:17671689 | lifeskim:mentions | umls-concept:C0086418 | lld:lifeskim |
| pubmed-article:17671689 | lifeskim:mentions | umls-concept:C0007102 | lld:lifeskim |
| pubmed-article:17671689 | lifeskim:mentions | umls-concept:C1516334 | lld:lifeskim |
| pubmed-article:17671689 | lifeskim:mentions | umls-concept:C0334227 | lld:lifeskim |
| pubmed-article:17671689 | lifeskim:mentions | umls-concept:C0021743 | lld:lifeskim |
| pubmed-article:17671689 | lifeskim:mentions | umls-concept:C0249197 | lld:lifeskim |
| pubmed-article:17671689 | lifeskim:mentions | umls-concept:C0205263 | lld:lifeskim |
| pubmed-article:17671689 | pubmed:issue | 3 | lld:pubmed |
| pubmed-article:17671689 | pubmed:dateCreated | 2007-8-2 | lld:pubmed |
| pubmed-article:17671689 | pubmed:abstractText | Type I interferon (IFN) was originally identified as an immunomodulatory cytokine because of its antiviral activity. Further characterization of its biological effects revealed a prominent role in the direct control of cell growth and potent immunomodulatory and antiangiogenic actions. IFN-alpha and IFN-beta had both been classified as type I IFN, but differences in their antitumor activities were reported. We confirmed the difference in the antiproliferative activities of IFN-alpha2b and IFN-beta toward HT29 and SW480 cells. IFN treatment was observed to prolong cell cycle progression; in particular, the accumulation of S-phase population was one of the most characteristic changes. The prolongation of S-phase progression and transition into G2/M-phase was suggested to be a crucial action of type I IFN on colon cancer. Additionally, IFN activated the p21 promoter gene and induced p21WAF1/CIP1 expression. Furthermore, the cell cycle prolongation effect of IFN was suppressed when p21 expression was downregulated. Therefore, we confirmed that p21WAF1/CIP1 was a crucial target molecule for the effects of IFN on the cell cycle. Additionally, the ability of p21 induction differed between IFN-alpha2b and IFN-beta and correlated with their inhibitory activities toward cell growth. We conclude that type I IFN prolongs cell cycle progression by p21WAF1/CIP1 induction in human colon cancer cells. | lld:pubmed |
| pubmed-article:17671689 | pubmed:language | eng | lld:pubmed |
| pubmed-article:17671689 | pubmed:journal | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:17671689 | pubmed:citationSubset | IM | lld:pubmed |
| pubmed-article:17671689 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:17671689 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:17671689 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:17671689 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:17671689 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:17671689 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:17671689 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:17671689 | pubmed:status | MEDLINE | lld:pubmed |
| pubmed-article:17671689 | pubmed:month | Sep | lld:pubmed |
| pubmed-article:17671689 | pubmed:issn | 1019-6439 | lld:pubmed |
| pubmed-article:17671689 | pubmed:author | pubmed-author:TanakaShinyaS | lld:pubmed |
| pubmed-article:17671689 | pubmed:author | pubmed-author:TodoSatoruS | lld:pubmed |
| pubmed-article:17671689 | pubmed:author | pubmed-author:NakagawaTakah... | lld:pubmed |
| pubmed-article:17671689 | pubmed:author | pubmed-author:KamiyamaToshi... | lld:pubmed |
| pubmed-article:17671689 | pubmed:author | pubmed-author:NishiharaHiro... | lld:pubmed |
| pubmed-article:17671689 | pubmed:author | pubmed-author:NakanishiKazu... | lld:pubmed |
| pubmed-article:17671689 | pubmed:author | pubmed-author:IsekiKenK | lld:pubmed |
| pubmed-article:17671689 | pubmed:author | pubmed-author:KamiyamaNaoya... | lld:pubmed |
| pubmed-article:17671689 | pubmed:author | pubmed-author:KatayamaTomon... | lld:pubmed |
| pubmed-article:17671689 | pubmed:issnType | Print | lld:pubmed |
| pubmed-article:17671689 | pubmed:volume | 31 | lld:pubmed |
| pubmed-article:17671689 | pubmed:owner | NLM | lld:pubmed |
| pubmed-article:17671689 | pubmed:authorsComplete | Y | lld:pubmed |
| pubmed-article:17671689 | pubmed:pagination | 613-20 | lld:pubmed |
| pubmed-article:17671689 | pubmed:dateRevised | 2011-11-17 | lld:pubmed |
| pubmed-article:17671689 | pubmed:meshHeading | pubmed-meshheading:17671689... | lld:pubmed |
| pubmed-article:17671689 | pubmed:meshHeading | pubmed-meshheading:17671689... | lld:pubmed |
| pubmed-article:17671689 | pubmed:meshHeading | pubmed-meshheading:17671689... | lld:pubmed |
| pubmed-article:17671689 | pubmed:meshHeading | pubmed-meshheading:17671689... | lld:pubmed |
| pubmed-article:17671689 | pubmed:meshHeading | pubmed-meshheading:17671689... | lld:pubmed |
| pubmed-article:17671689 | pubmed:meshHeading | pubmed-meshheading:17671689... | lld:pubmed |
| pubmed-article:17671689 | pubmed:meshHeading | pubmed-meshheading:17671689... | lld:pubmed |
| pubmed-article:17671689 | pubmed:meshHeading | pubmed-meshheading:17671689... | lld:pubmed |
| pubmed-article:17671689 | pubmed:meshHeading | pubmed-meshheading:17671689... | lld:pubmed |
| pubmed-article:17671689 | pubmed:meshHeading | pubmed-meshheading:17671689... | lld:pubmed |
| pubmed-article:17671689 | pubmed:meshHeading | pubmed-meshheading:17671689... | lld:pubmed |
| pubmed-article:17671689 | pubmed:meshHeading | pubmed-meshheading:17671689... | lld:pubmed |
| pubmed-article:17671689 | pubmed:meshHeading | pubmed-meshheading:17671689... | lld:pubmed |
| pubmed-article:17671689 | pubmed:meshHeading | pubmed-meshheading:17671689... | lld:pubmed |
| pubmed-article:17671689 | pubmed:meshHeading | pubmed-meshheading:17671689... | lld:pubmed |
| pubmed-article:17671689 | pubmed:year | 2007 | lld:pubmed |
| pubmed-article:17671689 | pubmed:articleTitle | Type I interferon prolongs cell cycle progression via p21WAF1/CIP1 induction in human colon cancer cells. | lld:pubmed |
| pubmed-article:17671689 | pubmed:affiliation | Department of General Surgery, Hokkaido University Graduate School of Medicine, Sapporo, Japan. tomonari@f4.dion.ne.jp | lld:pubmed |
| pubmed-article:17671689 | pubmed:publicationType | Journal Article | lld:pubmed |
| entrez-gene:1026 | entrezgene:pubmed | pubmed-article:17671689 | lld:entrezgene |
| http://linkedlifedata.com/r... | entrezgene:pubmed | pubmed-article:17671689 | lld:entrezgene |
| lhgdn:association:5160 | lhgdn:found_in | pubmed-article:17671689 | lld:lhgdn |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:17671689 | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:17671689 | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:17671689 | lld:pubmed |
